CompletedNCT04723147
Carbidopa-levodopa for depression with loss of interest
About this title
Read the official source — NCT04723147Medication studyAges 25–55United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 25 years to 55 years. Other eligibility criteria applied.
- Listed locations
- AtlantaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: January 29, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 19
- Sponsor
- Emory University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 25 Years to 55 Years
- Official registry ID
- NCT04723147
- Official title
Show the full official title
Dopaminergic Therapy for Inflammation-Related Anhedonia in Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Atlanta
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Emory University, a university.
Did this study involve medication?
Yes. The study involved medication, including Carbidopa Levodopa and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 25 years to 55 years. Other eligibility criteria applied.
